Literature DB >> 11429649

Myosin light chain kinase and the onset of labour in humans.

F Moore1, A L Bernal.   

Abstract

Myosin light chain kinase (MLCK) is essential for myometrial contractions induced by calcium-mobilizing agonists. From the gene of vertebrate smooth muscle/non-muscle MLCK there are at least four proteins expressed. We have found that both a > 200 and a 137 kDa MLCK are equally expressed in human non-pregnant (NP) and term pregnant (P) uterine smooth muscle and confirmed that 19 kDa telokin (TK) is only expressed in P myometrium. In addition, we have observed that a MLCK immunogen at approximately 60 kDa is only expressed in NP myometrium, suggesting that its expression is inhibited during normal pregnancy in a hormonally dependent manner. However, when we compared pregnant myometrium from patients delivered preterm (PT) (< 34 weeks gestation), but not in labour (NIL), with PT patients in labour (IL) we found that PT(IL) samples expressed the approximately 60 kDa MLCK immunogen and thus displayed a NP phenotype whereas PT(NIL) samples did not express the protein and retained a pregnant phenotype. We hypothesize that the novel approximately 60 kDa MLCK immunogen contributes to the aberrent contractility associated with preterm labour. Experimental Physiology (2001) 86.2, 313-318.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11429649     DOI: 10.1113/eph8602188

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  2 in total

1.  Preliminary research on myosin light chain kinase in rabbit liver.

Authors:  B Ren; H Q Zhu; Z F Luo; Q Zhou; Y Wang; Y Z Wang
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

2.  Labor induction with oxytocin in pregnant rats is not associated with oxidative stress in the fetal brain.

Authors:  Tusar Giri; Jia Jiang; Zhiqiang Xu; Ronald McCarthy; Carmen M Halabi; Eric Tycksen; Alison G Cahill; Sarah K England; Arvind Palanisamy
Journal:  Sci Rep       Date:  2022-02-24       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.